genu
flaviviru
compos
differ
close
relat
speci
mani
flavivirus
arthropodborn
caus
signific
human
diseas
among
four
serotyp
dengu
viru
denv
yellow
fever
viru
yfv
west
nile
viru
wnv
japanes
enceph
viru
jev
categor
emerg
global
pathogen
jev
mosquitoborn
posit
sens
singl
strand
rna
viru
respons
frequent
epidem
enceph
predominantli
children
part
southeast
asia
adjoin
region
causal
factor
case
enceph
occur
everi
year
account
death
annual
seriou
neurolog
squeal
survivor
jev
expand
geograph
footprint
previous
nonendem
region
sever
billion
peopl
risk
japanes
enceph
je
repres
intern
emerg
concern
tropic
subtrop
countri
current
three
type
je
vaccin
use
inactiv
mousebrain
deriv
inactiv
cellcultur
deriv
live
attenu
cellcultur
deriv
howev
limit
usag
term
avail
cost
safeti
present
chemotherapi
jev
larg
support
target
toward
viru
lot
avenu
explor
past
also
current
tri
develop
safe
effect
molecul
would
abl
prevent
viru
replic
within
host
jev
genom
approxim
kb
length
carri
singl
long
open
read
frame
orf
flank
untransl
region
utr
utr
orf
encod
polyprotein
process
viral
cellular
proteas
three
structur
seven
non
structur
protein
utr
jev
genom
contain
conserv
sequenc
element
form
conserv
stem
loop
structur
utr
contain
secondari
structur
requir
format
translat
preiniti
complex
jev
requir
long
rang
rnarna
interact
region
genom
effici
replic
one
interact
occur
pair
complementari
nucleotid
locat
code
sequenc
capsid
protein
nucleotid
end
genom
cycliz
sequenc
commonli
denot
conserv
sequenc
locat
nucleotid
end
genom
highli
conserv
across
member
jev
serocomplex
indic
possibl
rna
element
within
utr
jev
genom
essenti
replic
antisens
oligonucleotid
shown
effect
use
therapeut
agent
viral
infect
one
studi
sirna
gener
cd
loopcod
sequenc
domain
ii
viral
envelop
protein
highli
conserv
among
flavivirus
essenti
role
membran
fusion
found
protect
lethal
enceph
similarli
sirna
also
gener
variou
nonstructur
protein
jev
found
effect
inhibit
viral
replic
antisens
approach
also
employ
inhibit
flavivir
replic
gener
antisens
molecul
rna
element
within
utr
flavivir
genom
one
approach
dnazym
utr
jev
genom
found
effect
control
viru
infect
murin
model
approach
differ
kind
antisens
oligonuleuotid
call
morpholino
flavivir
replic
inhibit
cultur
cell
well
anim
model
morpholino
oligom
singl
strand
dna
analogu
contain
nitrogen
base
dna
join
backbon
consist
morpholin
ring
phosphorodiamid
linkag
effici
deliveri
cell
morpholino
often
conjug
arginin
rich
peptid
howev
current
studi
use
differ
type
morpholino
oligom
call
vivomorpholino
one
secondari
structur
present
utr
jev
genom
vivomorpholino
special
type
nonpeptid
morpholino
oligom
conjug
new
transport
structur
provid
effect
deliveri
wide
varieti
tissu
live
anim
therebi
rais
possibl
use
therapeut
agent
transport
compris
dendrit
structur
assembl
around
triazin
core
serv
posit
eight
guanidinium
head
group
conform
effect
penetr
cell
membran
vivomorpholino
also
shown
effect
enter
function
within
cultur
cell
vivomorpholino
also
cost
effect
non
immunogen
stabl
physiolog
condit
compar
type
morpholino
studi
design
evalu
whether
use
vivomorpholino
therapeut
agent
possibl
experiment
model
je
intend
show
specif
design
vivomorpholino
effect
counter
viral
load
bodi
therebi
impart
signific
protect
anim
infect
lethal
dose
jev
anim
experi
approv
institut
anim
ethic
review
board
name
institut
anim
ethic
committe
nation
brain
research
centr
anim
experi
protocol
approv
anim
handl
strict
accord
good
anim
practic
defin
committe
purpos
control
supervis
experi
anim
cpcsea
ministri
environ
forestri
govern
india
vero
cell
kind
gift
dr
guruprasad
medigeshi
translat
health
scienc
technolog
institut
gurgaon
india
obtain
nation
centr
cell
scienc
pune
india
cell
grown
dmem
dulbecco
modifi
eagl
medium
supplement
fetal
bovin
serum
fb
antibiot
strain
jev
propag
suckl
balbc
mice
brain
harvest
symptom
sick
observ
tissu
suspens
made
mem
minimum
essenti
medium
follow
centrifug
g
final
filter
steril
filter
jev
titrat
plaqu
format
vero
cell
monolay
vero
cell
seed
sixwel
plate
form
semiconflu
monolay
h
cell
monolay
inocul
serial
dilut
viru
sampl
made
mem
contain
fb
incub
h
occasion
shake
inoculum
remov
aspir
monolay
overlaid
mem
contain
fb
lowmeltingpoint
agaros
cocktail
solut
gibco
invitrogen
corpor
grassland
ny
usa
contain
penicillin
streptomycin
amphotericin
b
plate
incub
h
plaqu
becam
visibl
allow
count
plaqu
cell
monolay
stain
crystal
violet
fix
cell
formaldehyd
vivomorpholino
mo
oligo
commerci
procur
gene
tool
llc
philomath
usa
mo
design
complementari
sequenc
jev
strain
genom
shown
tabl
oligonucleotid
target
specif
region
utr
jev
genom
rna
figur
base
scrambl
mo
random
sequenc
scmo
use
neg
control
experi
mo
sequenc
screen
blast
http
wwwncbinlmnihgovblast
primat
murin
mrna
sequenc
scmo
addit
screen
flavivir
sequenc
mo
procur
nanomol
quantiti
liquid
mm
stock
approxim
mgml
buffer
salin
dilut
steril
pb
achiev
desir
concentr
store
aliquot
five
six
week
old
balbc
mice
either
sex
randomli
distribut
group
sham
jevinfect
jevinfect
treat
scrambl
morpholino
jevscmo
jevinfect
treat
morpholino
viral
conserv
region
mo
jevinfect
treat
morpholino
secondari
structur
viral
rna
mo
initi
group
contain
anim
anim
belong
group
except
sham
infect
plaqu
form
unit
pfu
jev
strain
day
consid
day
zero
anim
sham
group
receiv
equal
volum
filter
mem
start
h
post
infect
day
zero
scmo
mo
mo
dilut
ml
steril
pb
correspond
mgkg
bodi
weight
administ
anim
belong
jevscmo
mo
mo
group
respect
per
day
consecut
day
anim
belong
shamtreat
group
receiv
equal
volum
steril
pb
surviv
anim
group
follow
jev
infect
morpholino
treatment
monitor
daili
upto
day
post
jev
infect
till
death
whichev
earlier
toxic
morpholino
mice
evalu
weight
loss
abnorm
behavior
clinic
observ
includ
tremor
ruffl
fur
hunch
ataxia
gait
abnorm
mask
manner
minim
bia
mous
cytokin
bead
array
cba
kit
use
quantit
measur
cytokin
level
mous
wholebrain
lysat
bead
mix
contain
popul
bead
distinct
fluoresc
intens
coat
captur
antibodi
differ
cytokin
wholebrain
lysat
incub
togeth
along
equal
volum
phycoerythrin
pe
conjug
detect
antibodi
h
room
temperatur
dark
bead
wash
resuspend
suppli
wash
buffer
bead
acquir
use
cell
quest
pro
softwar
fac
calibur
analyz
use
bd
cba
softwar
becton
dickinson
san
diego
ca
standard
curv
prepar
incub
suppli
mous
inflamm
standard
bead
mix
peconjug
detect
antibodi
protein
concentr
whole
brain
lysat
estim
bradford
method
sampl
volum
contain
protein
electrophores
polyacrylamid
gel
transfer
onto
nitrocellulos
membran
block
skim
milk
blot
incub
overnight
primari
antibodi
jev
eglycoprotein
abcam
usa
jev
kind
gift
dr
chunjung
chen
taichung
veteran
gener
hospit
taichung
taiwan
ino
upstatechemicon
usa
santa
cruz
biotechnolog
ca
usa
trx
ab
frontier
korea
kind
gift
dr
ellora
sen
nbrc
phospho
phospho
total
map
kinas
cell
signal
usa
dilut
extens
wash
blot
incub
appropri
secondari
antibodi
conjug
peroxidas
vector
laboratori
ca
usa
blot
wash
process
develop
use
chemiluminesc
reagent
millipor
usa
imag
captur
analyz
use
chemigeniu
bioimag
system
syngen
cambridg
uk
blot
strip
reprob
santa
cruz
biotechnolog
usa
determin
equival
load
sampl
immunohistochem
stain
brain
scarifi
anim
excis
follow
repeat
transcardi
perfus
icecold
salin
fix
paraformaldehyd
twenti
micron
thick
cryosect
made
help
leica
cryostat
process
immunohistochem
stain
detect
presenc
jev
antigen
brain
label
activ
microglia
section
incub
overnight
mous
antijev
antigen
nakayama
chemicon
ca
usa
rabbit
wako
osaka
japan
respect
wash
slide
incub
fitcconjug
antimous
antirabbit
secondari
antibodi
vector
laboratori
inc
burlingam
usa
follow
final
wash
section
section
cover
slip
mount
dapi
vector
laboratori
inc
slide
observ
zeiss
axioplan
fluoresc
microscop
zeiss
apotom
microscop
zeiss
gottingen
germani
respect
cryosect
brain
shamtreat
jevinfect
jevinfect
mo
treat
anim
rins
deioniz
water
follow
incub
thionin
dye
excess
dye
wash
slide
immers
alcoholdioxan
solut
differenti
two
chang
xylen
slide
mount
dpx
observ
leica
db
light
microscop
leica
microsystem
usa
level
ro
produc
within
brain
tissu
treatment
group
measur
cell
permeabl
nonpolar
probe
sigma
usa
diffus
cell
acet
group
cleav
intracellular
esteras
releas
correspond
dichlorodihydrofluorescein
deriv
subsequ
oxid
yield
fluoresc
adduct
dichlorofluorescein
trap
insid
cell
brain
homogen
treat
solut
follow
incub
dark
room
temperatur
min
rel
fluoresc
intens
measur
help
varioskan
flash
multimod
reader
thermo
electron
finland
excit
nm
emiss
nm
fluoresc
intens
intracellular
linear
indic
amount
cell
measur
mean
fluoresc
intens
normal
equal
concentr
protein
sampl
nitric
oxid
releas
brain
homogen
follow
mo
treatment
assess
use
griess
reagent
describ
previous
briefli
griess
reagent
sigma
st
loui
usa
ad
brain
homogen
incub
dark
min
intens
color
develop
estim
nm
help
benchmark
plu
elisa
plate
reader
biorad
ca
usa
amount
nitrit
accumul
calcul
standard
curv
construct
differ
concentr
sodium
nitrit
mous
neuroblastoma
cell
plate
five
mm
plate
densiti
cellsplat
cultur
h
h
serum
free
dmem
cell
either
mockinfect
steril
pb
infect
jev
multipl
infect
moi
h
cell
wash
twice
steril
pb
remov
nonintern
viru
three
four
plate
infect
jev
treat
scmo
mo
mo
concentr
plate
incub
h
serum
free
media
two
wash
pb
cell
first
fix
bd
cytofix
solut
bd
bioscienc
min
permeabil
resuspend
permeabil
buffer
bd
cytoperm
plu
bd
bioscienc
incub
least
min
cell
wash
twice
wash
buffer
pb
contain
bovin
serum
albumin
resuspend
wash
buffer
cell
per
primari
antibodi
jev
nakayama
strain
chemicon
usa
ad
dilut
incub
min
cell
wash
wash
buffer
pellet
centrifug
follow
incub
fitc
conjug
secondari
antibodi
min
final
wash
wash
buffer
cell
resuspend
fac
buffer
analyz
fac
calibur
percentag
popul
jevposit
cell
calcul
gate
popul
dot
plot
use
cell
quest
pro
softwar
bd
bioscienc
statist
analysi
perform
use
sigmastat
softwar
spss
inc
chicago
il
usa
data
compar
group
use
oneway
analysi
varianc
follow
post
hoc
test
differ
upto
p
consid
signific
mo
treatment
confer
signific
protect
mice
follow
jev
infect
surviv
mice
follow
jev
infect
dramat
increas
treatment
mo
approxim
anim
treat
mo
surviv
compar
surviv
anim
treat
post
infect
jev
figur
infect
jev
accompani
distinct
symptom
weight
loss
wherea
treatment
mo
post
jev
infect
prevent
anim
suffer
much
consider
chang
averag
bodi
weight
jevinfect
anim
treat
mo
observ
compar
anim
belong
jev
jev
scmo
group
show
signific
reduct
bodi
weight
day
post
infect
figur
symptom
associ
je
murin
model
observ
daili
basi
score
attribut
accordingli
anim
symptom
receiv
highest
score
observ
mo
treat
anim
score
lesser
belong
jevinfect
jevscmo
group
figur
assess
whether
mo
effect
reduct
viral
load
brain
homogen
brain
sampl
treatment
group
subject
plaqu
assay
describ
materi
method
section
number
pfuml
brain
homogen
found
significantli
higher
jev
jevscmo
group
compar
sham
p
viral
pfu
found
significantli
reduc
follow
mo
mo
treatment
compar
jevinfect
jevscmo
group
p
figur
valid
result
obtain
plaqu
assay
immunoblot
jevspecif
protein
perform
express
non
structur
protein
jev
significantli
increas
jev
jevscmo
group
compar
sham
p
level
found
significantli
reduc
mo
treatment
compar
jevinfect
group
p
similarli
e
glycoprotein
level
show
signific
increas
jevinfect
jevscmo
group
compar
sham
p
drastic
reduc
follow
mo
treatment
p
figur
immunostain
brain
section
show
greater
presenc
jev
antigen
jevinfect
jevscmo
group
wherea
mo
treatment
result
lesser
presenc
figur
character
inhibitori
effect
mo
jevinduc
neuron
death
brain
section
treatment
group
subject
thionin
stain
numer
healthi
cell
seen
section
obtain
sham
mo
mo
group
compar
section
belong
jevinfect
jevscmo
group
contain
numer
unhealthydi
neuron
alter
morpholog
figur
microgli
activ
increas
proinflammatori
cytokin
product
hallmark
jev
infect
see
whether
mo
treatment
help
vitiat
effect
immunostain
microgli
specif
marker
perform
brain
section
treatment
group
brain
section
jev
jevscmo
group
number
activ
microglia
characterist
morpholog
appear
frequent
compar
section
belong
sham
mo
mo
group
figur
cba
perform
check
proinflammatori
cytokin
level
brain
homogen
obtain
differ
treatment
show
level
found
significantli
increas
jev
jevscmo
group
compar
sham
infect
group
p
elev
level
proinflammatori
cytokin
drastic
reduc
mo
treatment
p
figur
increas
oxid
stress
cn
major
outcom
jev
infect
evalu
whether
mo
treatment
mice
result
abrog
oxid
stress
follow
jev
infect
measur
ro
level
brain
homogen
obtain
treatment
group
two
fold
increas
observ
ro
level
brain
sampl
jev
jevscmo
group
compar
sham
p
signific
reduct
ro
level
observ
mo
mo
group
compar
jevinfect
group
p
although
ro
level
decreas
mo
group
compar
jev
group
remain
significantli
higher
sham
p
figur
superoxid
dismutas
thioredoxin
protein
associ
oxid
stress
level
found
elev
approxim
jevinfect
jevscmo
group
respect
compar
sham
p
level
mo
mo
group
reduc
significantli
compar
jevinfect
group
p
level
also
found
increas
significantli
jevinfect
jevscmo
group
compar
sham
p
significantli
reduc
brain
sampl
obtain
mo
mo
group
compar
jevinfect
group
p
figur
e
heat
shock
protein
associ
intracellular
stress
signific
twelv
fold
increas
level
observ
jev
jevscmo
group
compar
sham
p
drastic
increas
level
jev
jevscmo
group
reduc
mo
mo
group
p
figur
c
jev
infect
lead
increas
nitric
oxid
product
cn
signific
two
fold
increas
seen
level
brain
sampl
obtain
jevinfect
jevscmo
group
compar
obtain
sham
p
level
subsequ
got
significantli
lower
level
follow
treatment
p
figur
immunoblot
analysi
show
nearli
increas
level
ino
jevinfect
jevscmo
group
compar
sham
p
ino
level
show
signific
decreas
mo
mo
group
compar
jevinfect
group
p
figur
h
western
blot
analysi
demonstr
signific
inhibit
express
differ
stress
relat
protein
whose
level
elev
follow
jev
infect
upon
mo
treatment
approxim
increas
level
jev
jevscmo
group
compar
sham
p
level
found
significantli
reduc
mo
mo
group
compar
jevinfect
group
p
figur
b
phospho
mapk
level
also
show
signific
increas
jev
jevscmo
group
compar
sham
p
level
also
found
reduc
significantli
follow
treatment
mo
compar
jevinfect
group
p
figur
c
phospho
level
found
significantli
increas
jev
jevscmo
group
compar
sham
p
level
phospho
show
consider
decreas
mo
mo
group
compar
jevinfect
group
p
figur
assess
whether
mo
effect
viral
load
vitro
cell
lysat
treatment
group
subject
plaqu
assay
pfuml
cell
lysat
found
significantli
higher
jev
jevscmo
group
compar
mockinfect
cell
p
viral
load
found
significantli
reduc
mo
mo
group
compar
jevinfect
group
p
figur
ascertain
result
obtain
plaqu
assay
intracellular
stain
jev
antigen
perform
number
jevposit
cell
count
flow
cytometri
total
gate
cell
found
posit
jev
antigen
mo
mo
group
respect
compar
jevinfect
group
jevscmo
group
figur
use
antisens
molecul
target
inhibit
viral
replic
investig
quit
sometim
though
applic
molecul
rais
possibl
futur
use
novel
therapeut
agent
mani
issu
regard
effect
term
stabil
deliveri
target
cell
recent
studi
involv
develop
techniqu
minim
elimin
issu
antisens
therapi
employ
wide
varieti
intract
diseas
splicemodifi
genet
defect
viral
diseas
role
variou
antisens
molecul
inhibit
replic
jev
report
posit
outcom
morpholino
oligom
singl
strand
antisens
molecul
exert
action
steric
block
complementari
rna
unlik
type
antisens
oligonucleotid
morpholino
provid
desir
properti
stabil
nucleas
resist
high
efficaci
longterm
activ
water
solubl
low
toxic
exquisit
specif
morpholino
oligom
use
previous
inhibit
flavivir
replic
includ
jev
though
util
peptid
base
morpholino
peptid
base
morpholino
contain
deliveri
moieti
evolv
natur
peptid
whose
activ
compon
arginin
residu
bioavail
structur
howev
argininebas
peptid
commerci
avail
research
purpos
greatest
efficaci
deliv
morpholino
cytosol
tissu
like
liver
leaki
muscl
would
consid
easili
deliver
result
reach
peptid
base
morpholino
wide
spectrum
tissu
remain
question
also
owe
peptid
natur
degrad
peptid
portion
conjug
found
time
tissu
depend
furthermor
applic
argininerich
peptid
transport
limit
due
high
cost
scalabl
stabil
ad
risk
immun
respons
peptid
limit
repeat
administr
diseas
requir
longterm
treatment
minim
problem
encount
peptideconjug
morpholino
octaguanidinium
dendrimerconjug
morpholino
oligom
develop
commonli
refer
vivomorpholino
mo
customsequ
antisens
molecul
report
enabl
morpholino
applic
adult
anim
mo
choic
antisens
molecul
enabl
us
test
specif
design
oligonucleotid
anim
well
cell
cultur
model
though
outstand
result
report
achiev
intraven
iv
administr
mo
prefer
intraperiton
rout
via
modest
system
deliveri
achiev
done
brain
report
ineffect
tissu
mo
administ
iv
though
direct
evid
show
mo
cross
blood
brain
barrier
administ
via
rout
accord
manufactur
gene
tool
llc
instruct
maximum
suggest
dosag
mammal
mgkg
hour
period
aim
determin
minimum
dose
desir
effect
could
achiev
initi
chosen
two
dose
mg
mg
per
kg
bodi
weight
bw
anim
found
signific
differ
surviv
rate
jevinfect
mo
treat
mice
either
dose
data
shown
mgkg
bw
surviv
rate
approxim
jevinfect
anim
treat
mo
anim
treat
mo
thu
decid
proceed
mgkg
bw
dose
subsequ
experi
plaqu
assay
brain
homogen
anim
group
reveal
number
infect
viral
particl
product
dramat
reduc
follow
mo
treatment
mo
gener
csi
region
jev
genom
interact
cs
region
locat
code
sequenc
capsid
protein
nucleotid
termin
genom
interact
result
cycliz
jev
genom
necessari
effici
replic
mo
target
toward
one
secondari
structur
utr
requir
format
translat
preiniti
complex
block
two
site
jev
genom
lead
like
effect
ie
inhibit
replic
translat
viral
genom
corrobor
decreas
express
viral
protein
e
glycoprotein
gener
flavivir
envelop
protein
brain
flavivir
known
possess
guanylyltransferas
activ
help
synthesi
methyl
cap
structur
end
viral
genom
play
crucial
role
translat
stabil
mrna
jev
e
glycoprotein
believ
involv
viral
adhes
entri
host
cell
hemagglutin
cellular
tropism
viral
virul
induct
protect
immun
respons
decreas
express
protein
indic
viral
replic
product
new
infect
viral
particl
inhibit
due
mo
immunohistochem
stain
viral
antigen
also
provid
visual
confirm
fact
jev
antigen
detect
much
lower
amount
brain
follow
mo
treatment
howev
data
prove
mo
directli
inhibit
infect
viral
particl
product
brain
conclus
state
whether
mo
reach
brain
data
mere
suggest
number
replicationcompet
infect
jev
brain
significantli
reduc
subsequ
lead
neuroprotect
well
known
jev
infect
caus
microgli
activ
activ
microglia
releas
array
chemic
mediat
detriment
neuron
brain
sinc
reduct
product
infect
viral
particl
follow
mo
treatment
studi
effect
microgli
pathophysiolog
mous
brain
result
show
significantli
reduc
number
activ
microglia
brain
section
motreat
anim
compar
jevinfect
jevinfect
scmo
treat
anim
sinc
littl
activ
microglia
proinflammatori
cytokin
level
brain
found
significantli
downregul
histochem
stain
also
reveal
neuron
popul
morpholog
remain
larg
unaffect
motreat
anim
brain
compar
jevinfect
jevinfect
scmo
treat
anim
gener
ro
gener
oxid
damag
implic
neurodegen
diseas
degrad
nervou
system
function
also
report
increas
follow
jev
infect
increas
ro
level
initi
variou
respons
within
cell
includ
damag
protein
dna
lipid
studi
ro
level
found
manyfold
increas
jevinfect
jevinfect
scmo
treat
anim
found
counteract
treatment
mo
level
stress
relat
protein
trx
also
found
posit
modul
follow
mo
treatment
known
antagonist
jev
shown
inhibit
jev
infect
prevent
viral
replic
studi
level
increas
brain
respons
jev
infect
possibl
due
upregul
induc
nitric
oxid
synthas
ino
treatment
mo
caus
decreas
basal
level
observ
shamtreat
anim
activ
regul
apoptot
gene
especi
therebi
check
activ
caspas
central
apoptot
process
jev
known
activ
via
pathway
brain
infect
anim
associ
apoptosi
jev
infect
also
shown
activ
stress
kinas
turn
result
activ
mapk
pathway
lead
apoptot
death
neuron
accord
establish
result
also
found
similar
activ
pattern
molecul
jevinfect
jevinfect
scmo
treat
anim
brain
sampl
treatment
mo
result
abrog
chang
led
greater
surviv
brain
neuron
observ
histochem
stain
activ
also
relat
transcript
activ
proinflammatori
gene
brain
thu
decreas
mapk
level
correl
decreas
level
proinflammatori
cytokin
level
obtain
brain
confirm
antivir
neuroprotect
properti
mo
observ
vivo
model
cultur
neuroblastoma
cell
infect
jev
follow
mo
treatment
though
mo
specif
develop
vivo
studi
also
known
taken
cell
cultur
condit
signific
decreas
viral
titer
sampl
obtain
cell
treat
mo
compar
either
jevinfect
jevinfect
scmo
treat
cell
reveal
plaqu
assay
data
support
fac
analysi
follow
intracellular
stain
jev
antigen
studi
undertaken
determin
antivir
neuroprotect
efficaci
vivomorpholino
experiment
model
je
consid
therapeut
agent
near
futur
studi
regard
antijev
effect
type
morpholino
oligom
though
none
yet
consid
therapeut
purpos
first
studi
investig
role
morpholino
oligom
special
design
effect
deliveri
live
anim
model
gener
ip
rout
administr
drug
prefer
anim
studi
rout
howev
efficaci
antisens
molecul
need
check
administ
applic
rout
ip
administr
human
uncommon
though
unheard
amount
oligom
requir
rout
administr
studi
mark
molecul
practic
therapeut
agent
je
though
studi
requir
recommend
clinic
trial
